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Peripheral blood mononuclear cellNinety-ﬁve percent of Leber hereditary optic neuropathy (LHON) patients carry a mutation in one out of
three mtDNA-encoded ND subunits of complex I. Penetrance is reduced and more male than female carriers
are affected. To assess if a consistent biochemical phenotype is associated with LHON expression, complex I-
and complex II-dependent adenosine triphosphate synthesis rates (CI-ATP, CII-ATP) were determined in
digitonin-permeabilized peripheral blood mononuclear cells (PBMCs) of thirteen healthy controls and for
each primary mutation of a minimum of three unrelated patients and of three unrelated carriers with normal
vision and were normalized per mitochondrion (citrate synthase activity) or per cell (protein content). We
found that in mitochondria, CI-ATP and CII-ATP were impaired irrespective of the primary LHON mutation
and clinical expression. An increase in mitochondrial density per cell compensated for the dysfunctional
mitochondria in LHON carriers but was insufﬁcient to result in a normal biochemical phenotype in early-
onset LHON patients.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Leber hereditary optic neuropathy (LHON) is a mitochondrial
genetic disorder characterized by a bilateral (sub)acute, painless
optical atrophy occurring in previously healthy patients. More than
95% of the patients with LHON carry one of the three “primary”
mtDNA mutations at position m.11778GNA, m.14484TNC, and
m.3460GNA [1]. All three mutations occur in genes that encode the
ND subunits of complex I (NADH:ubiquinone oxidoreductase, EC
1.6.5.3). Complex I is a large, multisubunit enzyme comprised of 7
mtDNA-encoded (ND1–ND6 and ND4L) and 38 nuclear-encoded
polypeptides [2]. It removes electrons fromNADH and passes them on
to the electron acceptor ubiquinone. For each pair of electrons, four
protons are transferred from the matrix across the inner membrane,
which creates the electrochemical gradient that drives the synthesis
of ATP from adenosine diphosphate and inorganic phosphate.
Biochemical data on mutation carriers and patients are only
scarcely available and do not show a constant picture. Complex I
activity measured in platelets, PBMC, lymphoblasts, EBV-transformed
blood lymphocytes, and cybrids of affected and unaffectedy, P.O. Box 2040, 3000 CA
x: +31 10 704 4747.
).
s, University Medical Centre,
ll rights reserved.m.3460GNA carriers was reduced to 50–80%, whereas in
m.11778GNA and m.14484TNC carriers, complex I activity is normal
or only mildly reduced [3]. Complex I-dependent ATP production was
decreased by 20% in leukocytes from four patients carrying the
m.14488TNC mutation [4]. In lymphocytes from two patients carrying
the m.11778GNA mutation, ATP synthesis decreased by about 50%
using complex I substrates and by about 60% using complex II
substrates [5]. In cybrids constructed by cell fusions of enucleated
ﬁbroblasts with rho° 206 cells from a total of six LHON patients
harboring the m.3460GNA, m.11778GNA, or m.14484TNC mutation,
complex I-dependent ATP synthesis was severely impaired
(m.3460GNA and m.14484TNC more than 90% and m.11778GNA
65%), while complex II-dependent ATP synthesis was not affected [6].
LHON is characterized by strongly reduced penetrance. Approxi-
mately 30–50% of males and 10–20% of female LHON mutation
carriers become symptomatic at a median age of 19 years (range 5–
56 years) [7]. Apparently, the mtDNA mutation is necessary but not
sufﬁcient to induce the clinical expression of LHON [8]. Age and
gender are the most important risk factors, although the underlying
mechanism remains obscure, and thus far unidentiﬁed secondary
genetic, epigenetic, and/or environmental might contribute to the
variable expression of this disorder. In the present study, we
investigated if a biochemical phenotype is associated with vision
loss in primary LHONmutation carriers. As PBMCs represent an easily
obtainable source of tissue that presents advantages over the use of
ﬁbroblasts or lymphoblast cell lines for research on oxidative
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gations on PBMC.
2. Materials and methods
2.1. Control subjects, carriers, and patients
The control group consisted of 13 subjects (6 males and 7 females,
mean age 27.9±4.1 years). The group with a LHON mtDNA mutation
consisted of 26 unrelated subjects (15 males and 11 females, mean age
45.3±19.7 years) ofwhich9were carrierswithnormal vision (LHON−):
m.3460GNA (n=3), m.11778GNA (n=3), and m.14484TNC (n=3) and
17 were visually impaired carriers (LHON+): m.3460GNA (n=5),
m.11778GNA (n=8), and 14484TNC (n=4) (Table 1).
To minimize the chance that the LHON− group could be
compromised by subjects who might be unaffected at the time of
investigation but could lose their vision later in life, we only
included unaffected carriers above the age at which the majority of
the patients have become symptomatic. The peak age of LHON
onset is between the age of 15 and 30 years and 95% of carriers who
will experience visual failure (10–20% of the female carriers) will do
so before the age of 50 years [9]. Therefore, only subjects with age
≥30 years were included in the LHON− group. All patient studies
were performed as part of the diagnostic service, and therefore,
approval of the ethical committee was not required. Patients (and
controls) were informed according to hospital guidelines and Dutch
legislation that residual material could be used for scientiﬁc
research and they did not object.
2.2. Isolation, cryostorage, and thawing of peripheral blood mononuclear
cells
Isolation of PBMCs from blood anti-coagulated with 0.18% EDTA
has been described in detail elsewhere [10]. The cells were carefully
resuspended in a small volume of (in mM) 250 sucrose, 10 HEPES
(pH 7.4), and 1 EDTA (SHE).Table 1
Characteristics of subjects.
LHON+ Gender Mutation Haplo group Age Age at onset
1 M m.3460 GNA J 21 20
2 M m.3460 GNA J 22 23
3 F m.3460 GNA H 40 15
4 M m.3460 GNA K 64 62
5 F m.3460 GNA H 73 16
6 M m.11778 GNA J 14 13
7 M m.11778 GNA H 19 19
8 M m.11778 GNA H 21 17
9 M m.11778 GNA H 46 36
10 M m.11778 GNA H 47 4
11 M m.11778 GNA H 49 34
12 M m.11778 GNA ⁎ 55 53
13 M m.11778 GNA T 61 56
14 M m.14484 TNC J 17 16
15 M m.14484 TNC J 28 23
16 M m.14484 TNC J 41 12
17 M m.14484 TNC ⁎ 60 49
LHON− Gender Mutation Haplo group Age
1 F m.3460 GNA J 37
2 F m.3460 GNA H 46
3 F m.3460 GNA ⁎ 74
4 F m.11778 GNA H 50
5 F m.11778 GNA J 54
6 F m.11778 GNA ⁎ 67
7 F m.14484 TNC J 30
8 F m.14484 TNC K 55
9 F m.14484 TNC J 86For cryostorage, PBMCs were further diluted in RPMI containing
20% newborn calf serum (NBCS) to 20×106 cells/mL, kept for 30 min
at 4 °C, after which an equal volume of ice-cold RPMI with 20% NBCS
and 20% dimethyl sulfoxide was carefully added. Next, the cell
suspension was transferred to 1-mL cryogenic vials in a Nalgene
freezing container (Wessington Cryogenics), incubated overnight at
−80 °C and stored in liquid nitrogen until use.
To study mitochondrial function, a cryovial with PBMCs was
warmed rapidly by swirling in a 37 °C water bath. Immediately after
thawing, the cells were washed three times with buffered saline (pH
7.4) containing 2 mM EDTA by centrifugation for 10 min at room
temperature. Next, the cells were carefully resuspended and cell
density adjusted to 10×106 cells/mL SHE. Cell viability was
determined by trypan blue exclusion and ranged from 70% to 90%. A
small sample was used to determine citrate synthase (CS) activity
according to Srere [11] and protein concentration by the Bio-Rad DC
protein assay (Bio-Rad Laboratories) with BSA as a standard. Complex
I activity was determined according to de Wit and Sluiter [10] and
complex II activity was measured by the method described by van
Raam et al. [12].
2.3. ATP synthesis assay
The ATP production by PBMCs was determined essentially as
described by Wanders et al. [13] for human skin ﬁbroblasts by
incubating 0.5×106 PBMCs/mL incubation medium consisting of
150 mM KCl, 25 mM Tris–HCl, 2 mM EDTA, 10 mM potassium
phosphate buffer (pH 7.4), 10 μM ADP, 0.1% BSA, and 15 μg/mL
digitonin in a 96-well black microplate (Optiplate; PerkinElmer) for
5 min at 37 °C to permeabilize the cells. As shown by Ouhabi et al.
[14], the addition of EDTA to the incubation medium is necessary
to prevent ATP hydrolysis by ATPase activities that are not lost
during permeabilization. To investigate if 2 mM EDTA indeed
inhibited these ATPase activities sufﬁciently during the ATP
production assay, 1 μM ATP was added to some control and
LHON PBMC samples, chosen at random, in the presence of 25 μM
atractyloside to inhibit mitochondrial ATP synthesis. Under these
conditions, not any statistically signiﬁcant decrease in ATP
concentration was demonstrable at various times during an
incubation period of 10 min showing that all ATPase activities
were blocked effectively. Consequently, the amount of ATP
produced by control and LHON PBMCs will not decrease by
simultaneous ATP hydrolysis. The complex I-dependent ATP
production was assessed in the absence and presence of 0.5 μM
of the speciﬁc complex I inhibitor rotenone, and started by adding
10 mM malate and 10 mM glutamate, and 0.6 mM malonate to
inhibit any complex II activity. To assay ATP synthesis via complex
II, the reaction was started by the addition of 10 mM succinate in
the absence and presence of 100 mM of the competitive complex II
inhibitor malonate, with 0.5 μM rotenone to prevent the formation
of oxaloacetate that otherwise would inhibit complex II very
strongly. Next, the microplate was gently shaken and incubated at
37 °C. After 30 min, the reaction was stopped by the addition of
ATPLite (PerkinElmer) containing lucigenin and luciferase, the plate
shaken, and next chemiluminescence measured by a TopCount NSX
Scintillation Counter (PerkinElmer) using ATP as a standard. The
net rate of complex I- and II-dependent ATP synthesis was
calculated by subtraction of the rate in the presence of the
respective speciﬁc complex I or II inhibitor from that in its
absence. By assessing the ATP concentration at various times,
control PBMCs were found to form ATP on glutamate/malate and
on succinate as a statistically signiﬁcant linear function of time up
to 30 min of incubation (R2=0.9932 and Pb 0.001; R2=0.9824
and Pb 0.001). Therefore, the ATP synthesis rate was expressed as a
single value in nanomoles of ATP synthesized per 30 min per
milliunit of CS or per milligram of cell protein.
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Mitochondria were isolated from PBMCs and processed for two-
dimensional blue native PAGE as previously described [12]. In short,
after lysis by digitonin (4 g/g mitochondrial protein) 200 μg of
mitochondrial protein was separated by BN-PAGE on a 5–13%
acrylamide gradient gel. Strips from that ﬁrst dimension were then
excised, reduced for 1 hour at room temperature in 1% SDS containing
4 μL/mL tributylphosphine, and used for second dimension SDS–
(12%) PAGE. After Western transfer onto a PVDF membrane using
CAPS buffer (10mM3-[cyclohexylamino]-1-propane sulfonic acid, pH
11, 10% methanol), the cornerstone subunit of each of the ﬁve
OXPHOS complexes were visualized with the OXPHOS Western
blotting kit (MS601; Mitosciences), biotinylated anti-mouse IgG
(RPN1001, Amersham Biosciences), streptavidin-biotinylated horse-
radish peroxidase complex (RPN1051; Amersham), and SuperSignal
West Femto (Pierce). Images were acquired using a calibrated
densitometer (GS-800; Bio-Rad) and the PDQuest software package
(version 6.2.1; Bio-Rad).
2.5. Measurement of mitochondrial proton leak
To assess the magnitude of the proton leak the mitochondrial
membrane potential (Δψm) and state 2 respiration, deﬁned as
respiration in the presence of substrates without adenylates, was
measured simultaneously in PBMCs from ﬁve controls and six LHON
patients by a multisensor high-resolution respirometer (O2k-
MiPNetAnalyzer; Oroboros Instruments) equipped with a tetraphe-
nylphosphonium (TPP+)-selective electrode ﬁlled with 10 mM
TPP+Cl− and a 2-mm DriRef™ reference electrode (World Precision
Instruments). Respirometric analysis was performed on-line using
DatLab 4.3 software (Oroboros), and the rates of oxygen consumption
were expressed as picomoles of O2 per second per milligram of
protein (pmol O2 s−1 mg−1 protein). After a starvation period of
2 hours to increase the extremely low-PBMC oxygen consumption
[12] by incubating 1.5–3.0×106 cells/mL at 37 °C under constant
stirring (750 rpm) in proton leak buffer containing KCl (120 mM),
KH2PO4 (3 mM), Tris (50 mM) and fatty acid-free BSA (0.25%, wt./
vol.), pH 7.35, rotenone (5 μM), and oligomycin (1 μg/mL) were
added, the PBMCs were permeabilized by 30 μg digitonin/106 cells,
and the oxygen chamber was closed. After calibrating the TPP+
electrode by successive additions of TPP+ up to 1.5 μM using aFig. 1. Comparison of the rates of complex I- (A) and complex II-dependent (B) ATP synthesis
determined by incubating 0.5×106 PBMC per milliliter of incubation medium containing 2m
malate and 0.6mMmalonate to inhibit complex II with orwithout 0.5 μMrotenone (CI-ATP),
The ATP concentration at the end of incubation period was assessed by the ATPLite 1step as
subtracting the ATP concentration in the presence of the respective speciﬁc inhibitor from th
Data are expressed as the mean±SD. ⁎Pb0.05 and ⁎⁎Pb0.001 versus control.titration-injection micropump (Oroboros), the PBMC mitochondria
were energized by the addition of 2.5 mM succinate. Unfortunately,
accurate titration of the still low oxygen consumption rate with
malonate was impossible. Instead, 1 μM carbonyl cyanide p-
triﬂuoromethoxyphenylhydrazone was added to release TPP+ for
baseline correction. The calculation of Δψm was obtained from the
Nernst equation using a TPP+-binding mean correction factor of 0.13
[15], and an estimated intra-mitochondrial volume of 1 μL/mg of
protein [16].
2.6. Statistical analysis
Statistical analyses were performed with Stata/SE 10.1 software
(StataCorp LP, College Station, TX). The results were expressed as the
mean±standard deviation (SD). Skewness/kurtosis tests for normal-
ity showed that the data obtained for CI-ATP permilliunit of CS and CI-
ATP per milligram of protein were normally distributed and for
mitochondrial density, CII-ATP per milliunit of CS, and CII-ATP per
milligram of protein after natural logarithm transformation. Differ-
ences between groupswere then evaluated on the basis of Student's t-
test or one-way analysis of variance where appropriate. When
signiﬁcant F values were obtained, individual group means were
tested for differences according to Bonferroni's a posteriori correction
for multiple comparisons. The criterion for signiﬁcance was Pb0.05
for all comparisons.
As a consequence of the fact that more male than female carriers
are affected, our goal to classify the LHON mutation carriers based on
the clinical expression of the disease, i.e., into a group of LHON
patients and a group of carriers without vision loss, implies a strong
bias on gender. Therefore, any analysis on gender is meaningless.
Linear regression analyses of CI-ATP and CII-ATP per milliunit of CS
on age indicated a marginal (R2=0.20) but signiﬁcant (Pb0.005) age
effect that was lost after patient 9 of the LHON− group (86 years of
age) was omitted from the database. Therefore, that patient was not
taken into further account.
To examine if early- and late LHON+ differ in their ability to
compensate per cell for the impaired mitochondrial-dependent ATP
synthesis, a Kruskall–Wallis equality-of-populations rank test and a
two-sample Kolmogorov–Smirnov test for equality-of-distribution
functions were performed after assigning the distinction “positive” to
values of CI-ATP per milligram of protein that were equal or higher
than the lowest control value and else “negative.”of PBMCmitochondria between controls, LHON− and LHON+. The ATP production was
M EDTA to inhibit ATPase activities during 30 min in the presence of 10mM glutamate/
or of 10mM succinate and 0.5 μMrotenonewith orwithout 100mMmalonate (CII-ATP).
say of PerkinElmer (Zaventem, Belgium). The net CI-ATP and CII-ATP was calculated by
at in its absence and expressed as nanomoles of ATP/30 min/mU citrate synthase (CS).
Fig. 2. Supercomplex organization of OXPHOS complexes in PBMCmitochondria from a
control (A) and a LHON mutation carrier (B). After solubilization of equal amounts of
mitochondrial membranes with digitonin, supercomplex separation was achieved by
1D blue native electrophoresis followed by 2D SDS–PAGE to resolve the composition of
each of the supercomplexes. The cornerstone subunits of each of the ﬁve OXPHOS
complexes were visualized with the OXPHOS Western blotting kit (MS601; Mitos-
ciences), biotinylated anti-mouse IgG (RPN1001, Amersham Biosciences), streptavidin-
biotinylated horseradish peroxidase complex (RPN1051; Amersham) and SuperSignal
West Femto (Pierce). Images were acquired using a calibrated densitometer (GS-800;
Bio-Rad) and the PDQuest software package (version 6.2.1; Bio-Rad).
Fig. 3. Respiration-driven proton leak in PBMC from control (○) (n=5) and LHON (●)
(n=6) subjects. The mitochondrial membrane potential (mV) and state 2 respiration
rate (pmol O2 per sec and per mg protein) achieved by addition of 2.5 mM succinate in
the absence of adenylates were measured simultaneously in 1.5–3.0×106 digitonin-
permeabilized PBMC per milliliter of proton leak buffer consisting of KCl (120 mM),
KH2PO4 (3 mM), Tris (50 mM) and fatty acid-free BSA (0.25%, wt./vol.), pH 7.35,
rotenone (5 μM), and oligomycin (1 μg/mL) in a multisensor high-resolution
respirometer (Oroboros Instruments, Innsbruck, Austria) using tetraphenylphospho-
nium-selective electrodes. Data are expressed as the mean±SD.
Fig. 4. Mitochondrial density of PBMC from controls (n=12), LHON− (n=8), and
LHON+ (n=17) as reﬂected by the expression of the mitochondrial matrix enzyme
citrate synthase (CS) expressed as milliunits of CS per milligram of cell protein. Data
represent the mean±SD. ⁎Pb0.05 versus control.
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3.1. Complex I- and II-dependent ATP production is decreased in
mitochondria of LHON mutation carriers
To ﬁnd out if mitochondrial function of LHON PBMC differed from
controls, the rate of ATP synthesis was assessed. The rates of ATP
synthesis driven by malate/glutamate (CI-ATP) and by succinate (CII-
ATP) were determined and normalized for CS activity. To prevent a
family-based bias in this study, we only included LHON mutation
carriers and patients who were unrelated. Obviously, this stringent
criterion limited the number of patients that could be included into
the study and unfortunately led to a stronger than usual bias on sex.
The affected group (LHON+) consisted of 88.2% males, and in the
unaffected group (LHON−), all subjects were female (Table 1). In our
previous studies [17–19], we found that 74.5% of the affected subjects
were male, and conversely, of the unaffected subjects, 70.9% were
female. Undoubtedly, due to the stringent inclusion criterion and the
fact that only 46 LHON families were available in the Netherlands, no
unaffected male LHON mutation carriers were included into the
present study. We found that CI-ATP per mitochondrion in the
LHON+ and LHON− group was 53% (Pb0.001) and 45% (Pb0.001),
respectively, lower than in the control group (0.38±0.10 nmol/
30 min/mU CS) (Fig. 1A).CII-ATP per mitochondrion of LHON+ PBMC was 57% lower
(Pb0.001) and of LHON− 42% lower (P=0.012) than controls
(0.18±0.04 nmol/30 min/mU CS) (Fig. 1B). There was no
statistically signiﬁcant difference between LHON+ and LHON−
regarding CI-ATP and CII-ATP per mitochondrion. The coefﬁcient of
intra-assay variation of the ATP synthesis measurements ranged
between 6% and 8%.
3.2. Supercomplex expression in PBMC mitochondria is not different
between control and LHON
It is surprising that a defect in complex I caused by an mtDNA
mutation in LHON has led to an impaired complex II-dependent ATP
Fig. 5. Mitochondrial density of PBMC from controls (n=10), LHON− (n=3), and LHON+ (n=5) as reﬂected by the expression of the mitochondrial inner membrane enzyme
complex II expressed as milliunits per milligram of cell protein (A) and the association of citrate synthase activity with the amount of complex II activity (B). ⁎Pb0.05 versus control.
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III, and IV appears essential for effective energy generation [20] and
any change in its composition and level of expression may interfere
with CII-ATP (via available complex III and IV) as well, we studied if
the expression of complex II and this process was impaired due to the
mutation in complex I explaining the impaired CI-ATP and CII-ATP.
Based on the knownmolecular masses of the OXPHOS complexes [20],
2D BN-PAGE of equal amounts of mitochondria showed that both in
control (Fig. 2A) and in LHON PBMC (Fig. 2B), the majority of complex
I apparently is bound to complex III and IV into a large supercomplex
of ∼1.5 MDa. The supercomplex did not differ in composition and in
magnitude of expression between control and LHON PBMC mito-
chondria. The faint spot with a molecular mass in-between 140-
232 kDamight represent a complex I subcomplex [21]. Complex II was
found as a monomer (∼140 kDa) only and the expression level was
comparable between control and LHON PBMC mitochondria (Fig. 2A
and B).
3.3. Proton leak is higher in LHON PBMC mitochondria
Recent data have shown that LHON ﬁbroblasts may share a
common mitochondrial coupling defect with other hereditary optic
neuropathies [22]. To establish if this is also the case in LHON PBMC asFig. 6. Complex I- (A) and complex II-dependent (B) ATP synthesis rates of control, LHON−, a
Fig. 1 for further details of the ATP synthesis assay. Data represent the mean±SD. ⁎⁎Pb0.0an explanation for the decreased CII-ATP, the respiration-driven
proton leak in control and LHON PBMC mitochondria was assessed.
Fig. 3 shows that the mitochondrial membrane potential of LHON
PBMC mitochondria was signiﬁcantly (P=0.013) lower than that of
control mitochondria. The oxygen consumption rates were not
signiﬁcantly different.
3.4. Mitochondrial density is increased in LHON mutation carriers
To study if the impaired respiratory chain-dependent ATP
synthesis by LHON+ and LHON− mitochondria might be compen-
sated by an increase in mitochondrial density, the amount of CS
activity of LHON and control PBMC serving as a marker for
mitochondrial mass [11,23] was determined. Mitochondrial density
was 53% higher (P=0.016) in LHON+ and 52% higher (P=0.044) in
LHON− compared to controls (81±17 mU CS/mg protein) (Fig. 4).
To reinforce the ﬁnding that mitochondrial density increased in
LHON mutation carriers and patients compared to controls, we
assessed the relationship between the level of expression of citrate
synthase, a marker of the mitochondrial matrix, and complex II as a
marker of the mitochondrial inner membrane, in a number of control,
LHON−, and LHON+ samples as well. We found higher complex II
levels in the two LHON groups compared to the control group (Fig.nd LHON+ PBMC expressed as nanomoles of ATP/30min/mg protein. See the legend of
01 versus control.
Fig. 7. Complex I-dependent ATP synthesis rates of PBMC from early-onset (≤24 years)
and late-onset (N24 years) LHON+ patients expressed as nanomoles of ATP/30 min/
mg protein. See the legend of Fig. 1 for further details of the ATP synthesis assay.
Individual data are shown; the dashed line representing the lowest normal value.
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two markers (R2=0.501, Pb0.001, n=18) (Fig. 5B).
3.5. Increased mitochondrial density per cell compensates reduced ATP
production per mitochondrion in carriers but not in LHON patients
To examine if the increase in mitochondrial density in PBMC
of LHON carriers and patients compensated the impaired rate of
mitochondrial-dependent ATP synthesis, we determined the ATP
synthesis rate per milligram of cell protein. Indeed, in LHON−, CI-ATP
per cell did not differ signiﬁcantly (22% lower, P=0.11) from controls
(29.8±7.7 nmol/30 min/mg protein), but in LHON+, CI-ATP per cell
was still 36% lower (Pb0.001) than controls (Fig. 6A).Moreover, in the
LHON+ group, early-onset (≤24 years) LHON PBMC had a signiﬁ-
cantly (P=0.03) lower ability than late-onset (N24 years) LHON
PBMC to synthesize ATP via complex I at least at the lowest normal
rate of 17 nmol ATP/30 min/mg protein (Fig. 7).
CII-ATPper cellwas41% lower (P=0.002) in LHON+, but in LHON−,
it was not signiﬁcantly lower (21%, P=0.36) than in controls
(14.5±4.4 nmol/30 min/mg protein) (Fig. 6B).
4. Discussion
The results of this study showed that in concurrence with previous
reports [4–6], CI-ATP by mitochondria of LHON mutation carriers was
impaired and that dysfunction of OXPHOS in LHON can be detected
using peripheral blood mononuclear cells. Furthermore, the results
showed that despite defective mitochondrial CI-ATP and CII-ATP,
OXPHOS-dependent ATP production per cell is not signiﬁcantly
impaired in unaffected LHON carriers.
Although impaired CI-ATP by PBMC mitochondria of LHON
mutation carriers could be explained by a dysfunctional complex I
due to the mutated ND gene, we found that complex I enzyme
activity of PBMC of ﬁve LHON+ and four LHON− determined in
vitro did not differ statistically signiﬁcantly from controls
(expressed as milliunit of complex I activity per unit of citrate
synthase activity, the means (and SD) amounted to 48.7 (23.5), 43.7(13.4), and 48.4 (19.4), respectively). Previously, Brown et al. [24]
reported varying outcomes of complex I activity in LHON as well.
This discrepancy between the in vitro and in situ situation could be
due to the fact that complex I activity in vitro is determined under
optimal conditions, e.g., under saturating substrate concentrations,
and that most spectrophotometric assays are not directed to detect
a defective proton translocation. Importantly, that exempliﬁes the
relevance of in vivo measurements.
Our results not only showed impaired CI-ATP by PBMC
mitochondria of LHON carriers and patients but also impaired CII-
ATP. This is different to the ﬁndings of Baracca et al. [6] in LHON
cybrids, showing only impaired CI-ATP per cell. Because complex II
is encoded by nuclear genes [25] and the primary LHON mutations
are located in mtDNA, only a common mechanism can explain the
combined impaired CI-ATP and CII-ATP of LHON PBMC mitochon-
dria. Based on our measurements of the mitochondrial membrane
potential during state 2 respiration, we postulate an increased
proton leak in PBMC mitochondria of LHON mutation carriers,
suggesting that the decreased CII-ATP by PBMC mitochondria is a
secondary phenomenon resulting from a dysfunctional complex I
in those cells. Apparently, that phenomenon did not occur in freshly
cultured LHON cybrids and might need time to become effective [6].
Superoxide can damage the mitochondrial inner membrane through
the formation of peroxynitrite promoting proton leak [26]. Although
it is still under debate which is the exact site at complex I where
superoxide is generated [27], the levels of this reactive oxygen
species (ROS) increase when complex I does not function properly
[28,29]. Indeed, the levels of ROS in LHON mitochondria are higher
than normal [30,31].
We have found that the mitochondrial density in PBMC of
mutation carriers irrespective of the clinical status was higher than
in healthy controls. Recently, in non-arteritic anterior ischaemic optic
neuropathy such a phenomenon has been reported as well [32]. If
mitochondria are no longer capable of meeting cellular ATP demand,
via a complex signal transduction pathway involving AMP-activated
protein kinase [33] and the master switch, peroxisome proliferator-
activated receptor gamma coactivator 1α [34], the number of
mitochondria as a compensation will ﬁnally increase. Despite the
increased mitochondrial density, our data showed that this was not
sufﬁcient to effectively restore the cellular CI-ATP and CII-ATP in the
group of LHON patients (LHON+). In that respect, especially, a
subgroup of patients who lost their vision before the age of 24 years
was signiﬁcantly less successful than their counterparts who lost
vision later in life. A population-based clinical study of LHON in the
North East of England determined that 75% of LHON+ was younger
than 24 years [7], which might point out a fundamental difference in
etiology between early-onset LHON+ (age ≤24 years) and late-onset
LHON+ (age N24 years). The absence of a protective genetic modiﬁer
or the presence of a risk factor could contribute to the early-onset in
those patients.
In conclusion, we have shown that, in LHONmutation carriers, but
not in (early-onset) LHON patients, an increase in mitochondrial
density in PBMC fully compensated per cell the impaired CI-ATP and
CII-ATP. This provides a biochemical phenotype that might be useful
for prognostic predictions in mutation carriers and this subphenotype
may also help to identify new LHON modiﬁer genes in families. Our
data indicate that such a gene may be involved in mitochondrial
biogenesis.
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